Ionis Pharmaceuticals, Inc.
MODULATION OF HSD17B13 EXPRESSION
Last updated:
Abstract:
Provided herein are methods, compounds, and compositions for reducing expression of HSD17B13 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a liver disease, metabolic disease, or cardiovascular disease or disorder, including but not limited to NASH, in an individual.
Status:
Application
Type:
Utility
Filling date:
21 Mar 2019
Issue date:
7 Jan 2021